Nasdaq · Healthcare
Krystal Biotech, Inc. (KRYS)
As-reported financials and recent SEC filings for Krystal Biotech, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$389.1M
Net income
$204.8M
Net margin
52.6%
Diluted EPS
$6.84
ROE
16.8%
P/E (TTM)
49.8×
Market cap
$10.97B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2021 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| Gross profit | — | — | — | — | — |
| Operating income | $161.3M | $65.7M | $-109.6M | $-145.2M | $-68.3M |
| Net income | $204.8M | $89.2M | $10.9M | $-140.0M | $-69.6M |
| Diluted EPS | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →1442026-06-04
View on EDGAR →42026-05-27
View on EDGAR →1442026-05-26
View on EDGAR →Go deeper on KRYS
Search Krystal Biotech, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.